US biopharma company Gilead Sciences has licensed three preclinical antiviral programs, including investigational candidates having the potential to treat human rhinovirus, influenza and herpes viruses, from Swiss pharma company Novartis.
As per the agreement, Gilead Sciences will get exclusive global rights for the development and commercialization of small molecules against three undisclosed targets. Novartis will get an undisclosed upfront payment apart from an additional $291 million in the form of potential milestone payments based on certain development and commercial milestones, and also as royalties on yearly net sales.
John McHutchison – Gilead Sciences Chief Scientific Officer and Head of Research and Development, said: “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options.
The antiviral portfolio of Gilead Sciences includes drugs for the treatment of HIV, hepatitis B, and hepatitis C, and also influenza infection.